Use of anticholinergic drugs in patients with schizophrenia in Asia from 2001 to 2009

Pharmacopsychiatry

Volumn 44, Issue 3, 2011, Pages 114-118

  Xiang, Y T ^a,b   Wang, C Y ^b   Si, T M ^c   Lee, E H M ^a   He, Y L ^d   Ungvari, G S ^e   Chiu, H F K ^a   Yang, S Y ^f   Chong, M Y ^g   Tan, C H ^h   Kua, E H ^h   Fujii, S ⁱ   Sim, K ^j   Yong, K H ^j   Trivedi, J K ^k   Chung, E K ^l   Udomratn, P ^m   Chee, K Y ⁿ   Sartorius, N ^o   Shinfuku, N ^p  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY   (Taiwan)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ Hyogo Institute for Traumatic Stress   (Japan)

^j INSTITUTE OF MENTAL HEALTH   (Singapore)

^k KING GEORGE'S MEDICAL UNIVERSITY   (India)

^l Seoul Children's Hospital   (South Korea)

^m PRINCE OF SONGKLA UNIVERSITY   (Thailand)

ⁿ HOSPITAL KUALA LUMPUR   (Malaysia)

^o UNIVERSITY OF GENEVA   (Switzerland)

^p SEINAN GAKUIN UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENZATROPINE; BIPERIDEN; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MAZATICOL; PIROHEPTINE; PROCYCLIDINE; PROMETHAZINE; TRIHEXYPHENIDYL;

ADULT; ARTICLE; ASIA; CLINICAL FEATURE; DEMOGRAPHY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; ASIA; CHOLINERGIC ANTAGONISTS; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC STUDIES; FEMALE; HUMANS; MALE; MOVEMENT DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 79956116039     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1275658     Document Type: Article

References (40)

1. Carnahan RM, Lund BC, Perry PJ et al,. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006 113 135-141 (Pubitemid 43340907)
2. Lavin MR, Rifkin A. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy. J Clin Pharmacol 1991 31 769-777
3. Ungvari GS, Chiu HF, Lam LC et al,. Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 1999 19 141-148 (Pubitemid 29161959)
4. Brebion G, Bressan RA, Amador X et al,. Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs. Psychol Med 2004 34 369-374 (Pubitemid 38239645)
5. Minzenberg MJ, Poole JH, Benton C et al,. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004 161 116-124 (Pubitemid 38419316)
6. Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. Hosp Community Psychiatry 1991 42 580-581
7. Longo VG. Behavioral and electroencephalographic effects of atropine and related compounds. Pharmacol Rev 1966 18 965-996
8. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989 46 745-753 (Pubitemid 19198101)
9. Perris C, Dimitrijevic P, Jacobsson L et al,. Tardive dyskinesia in psychiatric patients treated with neuroleptics. Br J Psychiatry 1979 135 509-514 (Pubitemid 10214524)
10. Goff DC, Arana GW, Greenblatt DJ et al,. The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. J Clin Psychopharmacol 1991 11 106-112
11. Vagen R, Gotestam KG. An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients. Acta Psychiatr Scand 1986 74 519-523 (Pubitemid 17196676)
12. Chiu HF, Shum PS, Lam CW. Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital. Int J Soc Psychiatry 1991 37 187-191
13. Frackiewicz EJ, Sramek JJ, Herrera JM et al,. Ethnicity and antipsychotic response. Ann Pharmacother 1997 31 1360-1369 (Pubitemid 27498025)
14. Sim K, Su A, Fujii S et al,. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004 58 178-183 (Pubitemid 39043998)
15. Chong MY, Tan CH, Fujii S et al,. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004 58 61-67 (Pubitemid 38200373)
16. Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia changes and challenges. Int Rev Psychiatry 2008 20 460-468
17. APA. Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC, American Psychiatric Press 1997
18. Kane JM, Aguglia E, Altamura AC et al,. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998 8 55-66
19. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003 64 663-667 (Pubitemid 36750143)
20. WHO. Collaborating Centre for Drug Statistic Methodology: Guidelines for ATC Index with DDDs. Oslo, WHO, 2002
21. Chong MY, Tan CH, Shinfuku N et al,. Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: Comparison of REAP-2001 and REAP-2004 studies. Asia-Pacific Psychiatry 2010 2 77-84
22. Chong SA, Sachdev P, Mahendran R et al,. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust N Z J Psychiatry 2000 34 988-991
23. Wu RW. The combination of antipsychotics and anticholinergic medication. Chin Clin Doct 2001 29 33-34
24. Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983 140 490-491 (Pubitemid 13063702)
25. Zhang-Wong J, Beiser M, Zipursky RB et al,. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998 81 333-339 (Pubitemid 29049060)
26. Binder RL, Kazamatsuri H, Nishimura T et al,. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry 1987 144 1494-1496 (Pubitemid 18009548)
27. Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs 2000 7 205-211
28. Phillips MR, Lu SH, Wang RW. Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience. Am J Psychiatry 1997 154 1228-1234 (Pubitemid 27369173)
29. Double DB, Warren GC, Evans M et al,. Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand 1993 88 381-384 (Pubitemid 23337566)
30. Kane JM, Evans DL, Fiester SJ et al,. Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments. J Clin Psychiatry 1992 53 184-196
31. NICE. Schizophrenia. Full National Clinical Guideline on Core Intervention in Primary and Secondary Care. Trowbridge, Wiltshire, UK. (also: http://www.nice.org.uk/guidance/CG1/guidance/pdf/English) Cromwell Press 2003
32. WHO. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry 1990 156 412
33. Work Group on Schizophrenia. Practice Guideline for the Treatment of Patients with Schizophrenia. Second Edition. APA Practice Guidelines. Washington, DC, American Psychiatric Press 2004
34. Sim K, Su HC, Fujii S et al,. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol 2009 67 110-117
35. Xiang YT, Weng YZ, Leung CM et al,. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007 40 47-52
36. Greil W, Haag H, Rossnagl G et al,. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 1984 145 304-310 (Pubitemid 14066482)
37. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008 9 1451-1462 (Pubitemid 352005909)
38. Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. London, Martin Dunitz 2003
39. Xiang YT, Weng YZ, Leung CM et al,. Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia. Hum Psychopharmacol 2007 22 173-180
40. Leucht S, Wahlbeck K, Hamann J et al,. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003 361 1581-1589 (Pubitemid 36578993)